PL373391A1 - Terapia blokerem aldosteronu w profilaktyce lub leczeniu zaburzeń związanych z zapaleniem - Google Patents

Terapia blokerem aldosteronu w profilaktyce lub leczeniu zaburzeń związanych z zapaleniem

Info

Publication number
PL373391A1
PL373391A1 PL03373391A PL37339103A PL373391A1 PL 373391 A1 PL373391 A1 PL 373391A1 PL 03373391 A PL03373391 A PL 03373391A PL 37339103 A PL37339103 A PL 37339103A PL 373391 A1 PL373391 A1 PL 373391A1
Authority
PL
Poland
Prior art keywords
prevent
related disorders
treat inflammation
blocker therapy
aldosterone blocker
Prior art date
Application number
PL03373391A
Other languages
English (en)
Inventor
Richardo Rocha
Marc D. Zack
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of PL373391A1 publication Critical patent/PL373391A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL03373391A 2002-01-25 2003-01-24 Terapia blokerem aldosteronu w profilaktyce lub leczeniu zaburzeń związanych z zapaleniem PL373391A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35185102P 2002-01-25 2002-01-25

Publications (1)

Publication Number Publication Date
PL373391A1 true PL373391A1 (pl) 2005-08-22

Family

ID=32907588

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373391A PL373391A1 (pl) 2002-01-25 2003-01-24 Terapia blokerem aldosteronu w profilaktyce lub leczeniu zaburzeń związanych z zapaleniem

Country Status (12)

Country Link
US (1) US20040037806A1 (pl)
EP (1) EP1505983A2 (pl)
JP (1) JP2006508174A (pl)
KR (1) KR20050004774A (pl)
CN (1) CN1638777A (pl)
AU (1) AU2002368473A1 (pl)
BR (1) BR0307413A (pl)
CA (1) CA2478473A1 (pl)
MX (1) MXPA04007213A (pl)
PL (1) PL373391A1 (pl)
WO (1) WO2004073602A2 (pl)
ZA (1) ZA200405858B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755616B1 (en) * 2004-04-08 2013-08-14 Advanced Ocular Systems Limited Treatment of exudative retinopathy with mineralcorticoids
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN105294804A (zh) * 2015-12-07 2016-02-03 王海燕 一种治疗心力衰竭的药物组合物
WO2018027149A1 (en) * 2016-08-04 2018-02-08 University Of Miami Methods of treating alport syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299767A (en) * 1978-08-11 1981-11-10 Hoffmann-La Roche Inc. Benzodiazepine derivatives
DE4101841C2 (de) * 1991-01-23 1997-02-06 Schaper & Bruemmer Gmbh Verwendung von Sabal-Extrakten zum Behandeln von Mammakarzinomen
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
EP1028110B1 (en) * 1997-10-02 2004-04-14 Daiichi Pharmaceutical Co., Ltd. Novel dihydronaphthalene compounds and process for producing the same
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
AU2001280804A1 (en) * 2000-07-27 2002-02-13 Eileen R. Blasi Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6716829B2 (en) * 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders

Also Published As

Publication number Publication date
BR0307413A (pt) 2005-05-24
ZA200405858B (en) 2006-07-26
EP1505983A2 (en) 2005-02-16
MXPA04007213A (es) 2005-02-25
JP2006508174A (ja) 2006-03-09
WO2004073602A3 (en) 2004-12-16
KR20050004774A (ko) 2005-01-12
US20040037806A1 (en) 2004-02-26
CN1638777A (zh) 2005-07-13
WO2004073602A2 (en) 2004-09-02
CA2478473A1 (en) 2004-09-02
AU2002368473A1 (en) 2004-09-09

Similar Documents

Publication Publication Date Title
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
AU2003231344A1 (en) Selective nerve fiber stimulation for treating heart conditions
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
AU2003216162A1 (en) Iontophoretic treatment device
AU2003258305A8 (en) Combination therapy for treatment of fibrotic disorders
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2001280804A1 (en) Aldosterone blocker therapy to prevent or treat inflammation-related disorders
GB0320806D0 (en) Therapeutic treatment
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
GB0223367D0 (en) Therapeutic treatment
ZA200505989B (en) Use the steroids to treat ocular disorders
GB0223854D0 (en) Therapeutic treatment
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
PL373391A1 (pl) Terapia blokerem aldosteronu w profilaktyce lub leczeniu zaburzeń związanych z zapaleniem
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0210464D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
EP1671648A4 (en) PREVENTION AND TREATMENT OF GVHD
GB0313772D0 (en) Therapeutic treatment
AU2003273247A1 (en) Non-invasive methods to identify agents for treating pain
AU2003202255A8 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
AU2003297259A8 (en) Methods and compositions for treating neurological disorders
GB0211297D0 (en) Pain treatment
GB0225815D0 (en) Soil Treatment

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)